ArriVent BioPharma (AVBP) Treasury Shares (2023)

ArriVent BioPharma (AVBP) reported Treasury Shares of $150.0 million for Q4 2023.

ArriVent BioPharma (AVBP) Treasury Shares (2023) Analysis & Trends

ArriVent BioPharma (AVBP) has 1 years of Treasury Shares data on file, last reported at $150.0 million in Q4 2023.

For the quarter ending Q4 2023, Treasury Shares changed N/A year-over-year to $150.0 million; the trailing twelve-month figure through Dec 2023 stood at $150.0 million (changed N/A YoY), and the FY2023 full-year result was $150.0 million, changed N/A from the prior year.
Treasury Shares was little changed at $150.0 million in Q4 2023.
In the past five years, Treasury Shares ranged from a high of $150.0 million in Q4 2023 to a low of $150.0 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	ArriVent BioPharma	1.42 Bn	1.42 Bn	-	-

Download Data

Date	Value
Dec 31, 2023	150.00 Mn
Dec 31, 2023	150.00 Mn